Target intelligence / Profile preview

Non-viable burn eschar proteins

Molecular classification
Extracellular matrix protein, Structural protein, Denatured protein
01

Overview

Non-viable burn eschar proteins consist of the denatured extracellular matrix components, such as collagen and elastin, that result from thermal or chemical injury to the skin [1]. This necrotic tissue, known as eschar, forms a rigid layer that prevents natural wound healing and serves as a reservoir for microbial colonization and subsequent sepsis [1, 3]. In clinical practice, these proteins are the primary target for enzymatic debridement therapies, which aim to remove devitalized tissue without the trauma of surgical excision [2]. Proteolytic enzymes, such as those derived from bromelain or Clostridium histolyticum, interact with these proteins by breaking down the cross-linked, damaged fibers into soluble fragments [2, 4]. By selectively degrading the non-viable protein matrix, these treatments prepare the wound bed for spontaneous re-epithelialization or grafting [3]. Successful removal of these proteins is a critical step in burn management to reduce inflammation and promote the formation of healthy granulation tissue [1, 2].

Other names
Burn escharNecrotic burn tissueDenatured burn proteinsDevitalized burn tissueBurn wound necrotic debris
02

Mechanism of action

Enzymatic proteolysis and hydrolysis of denatured extracellular matrix proteins, specifically targeting damaged collagen and elastin within necrotic tissue while sparing viable dermis [2, 4].

03

Biological functions

Structural supportBarrier function
04

Disease associations

Burn injuryInfectionWound healing impairmentSepsis
05

Safety considerations

Risk of bleedingPain at application sitePotential damage to viable dermisHypersensitivity to enzyme components [2]Systemic absorption of proteolytic enzymes
06

Interacting drugs

Anacaulase-bcdb

5 more in the full profile.

07

Biomarkers

Visual eschar removalWound bed vascularizationPercentage of debridementTime to wound closure

Beyond the preview

Go deeper on Non-viable burn eschar proteins.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Non-viable burn eschar proteins.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call